• Biological Effects of Hemoadsorption in Septic Shock

  NCT07715110

  Not yet recruitingInterventionalNot ApplicableUpdated Jul 20, 2026
• CLinical Efficacy of Hemoperfusion With a Cytokine Adsorber in Norepinephrine-Resistant SEptic Shock

  NCT05136183

  Unknown statusInterventionalNot ApplicableUpdated Nov 29, 2021
• Effects of Hemoadsorption on Vascular Integrity in Septic Shock

  NCT07711197

  Not yet recruitingInterventionalNot ApplicableUpdated Jul 17, 2026
• Lipopolysaccharide Adsorption At Septic Shock

  NCT04827407

  CompletedInterventionalNot ApplicableUpdated Sep 19, 2024
• Selective Lipopolysaccharide Hemosorption in Maternal Sepsis

  NCT05711901

  CompletedInterventionalNot ApplicableUpdated Jun 25, 2024
• Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock

  NCT04884854

  CompletedObservationalUpdated Jun 3, 2021

ClinicalTrials.gov ID

NCT07661303

Lead Sponsor

Moscow Multidisciplinary Clinical Center "Kommunarka"OTHER_GOV

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

76Estimated

Last Update Posted

Jul 2, 2026Actual

Start Date

Jun 25, 2026Estimated

Primary Completion Date

Jun 25, 2027Estimated

Completion Date

Dec 25, 2027Estimated

Official Title

Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial

Brief Summary

Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial.

The goal of this clinical trial is the estimation of the efficacy and safety of hemoadsorption procedures (LPS (Lipopolysaccharide) and inflammatory mediators adsorption) in participants with septic shock.

The main questions it aims to answer are:

Does hemoadsorption decrease the severity of MODS (multiple organ disfunction syndrome)?

The study will include participants aged 18 to 80 years with a verified diagnosis of septic shock according to SEPSIS 3 criteria, diagnosed within 12 hours, and a SOFA (sequential organ failure assessment) score of 9 or more.

In addition to Standard of Care (SOC), blood purification, including hemoadsorption, will be used. The minimum waiting time after diagnosis of septic shock and initiation of basic therapy before inclusion of the patient in the study therapy is 4 hours.

The choice of procedure will be based on the EAA (Endotoxin Activity Assay) result:

• for an EAA level of 0.6-0.9, selective lipopolysaccharide (LPS) adsorption with duration from 2 to 10 hours;
• for an EAA level less than 0.6, inflammatory mediator adsorption with duration from 6 to 12 hours.

The choice of a specific adsorbers within the LPS and inflammatory mediator adsorption group will be based on randomization.

The use of LPS adsorption is planned based on randomization: Toramyxin R-20 or Efferon LPS. The use of inflammatory mediator adsorption is planned based on randomization: Jafron (HA 330) or CytoSorb.

Detailed Description

Every participant will receive 2 adsorption procedures. The second procedure will be initiated no later than 24 hours after the initiation of the first procedure.

LPS adsorption will be performed in 38 participants (Efferon LPS in 19 participants and Toramyxin in 19 participants), two procedures per participant.

Inflammatory mediator adsorption will be performed in 38 participants (Jafron HA 330 in 19 participants and CytoSorb in 19 participants), two procedures per participant.

Sample size calculations were performed separately for each treatment cohort. For the endotoxemia cohort (EAA level of 0.6-0.9), this randomized trial is designed to compare Efferron LPS and Toraymyxin with respect to change in SOFA score at 72 hours.

At present, no universally accepted minimal clinically important difference (MCID) has been established for the SOFA score in participants with septic shock. Therefore, the assumed treatment effect was derived from published evidence and expert clinical judgment.

In the EUPHAS trial, polymyxin B hemoperfusion was associated with a mean reduction in SOFA score of approximately 3.4 points at 72 hours, whereas minimal change was observed in the control group. Similarly, the LASSO study demonstrated substantial improvement in organ dysfunction following endotoxin adsorption therapy.

For the inflammatory mediator adsorption cohort (EAA level less than 0.6), this randomized trial is designed to compare CytoSorb and Jafron HA 330 with respect to change in SOFA score at 72 hours.

In the retrospective study Mehta et al., CytoSorb hemoperfusion was associated with a mean reduction in SOFA score of approximately 2.0 points after treatment in survival group. Similarly, the case series Onuk et al. demonstrated substantial improvement in organ dysfunction following inflammatory adsorption therapy with Jafron HA 330 with a mean reduction in SOFA score of approximately 3.5 points at 72 hours.

A between-group difference of 2.5 SOFA points was considered clinically meaningful for both Endotoxin hemoadsorption and inflammatory mediators hemoadsorption because it represents a substantial proportion of the treatment effect observed in previous hemoperfusion studies and corresponds to a clinically relevant difference in the degree of organ dysfunction improvement.

The sample size for both groups (LPS and inflammatory mediator adsorption) was calculated based on the following assumption: the primary endpoint was the change in SOFA score at 72 hours (ΔSOFA); the expected between-group difference - 2.5 points on the SOFA score; standard deviation of ΔSOFA - 2.5 points; equal allocation ratio (1:1); two-sided significance level (α) of 0.05; statistical power of 80%.

Sample size estimation was performed in R using the power.t.test() function. The calculation yielded a required sample size of 16.7 participants per group. Therefore, a minimum of 17 participants per group (34 participants in total) is required to achieve the planned statistical power.

To account for an anticipated 10% dropout rate, the final sample size will be 19 patients per group (38 participants in total for LPS+ 38 participants in total for Inflammatory mediators adsorption. 76 participants in total).

• Septic Shock

• Efferon LPS
• Toramyxin PMX 20R
• Jafron HA 330
• CytoSorb

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Septic shock according to SEPSIS-3 criteria
• Age: 18-80 years
• SOFA ≥9 points
• Diagnosis of septic shock established <12 hours ago
• Invasive hemodynamic monitoring
• Norepinephrine dose >0.2 mcg/kg/min

Exclusion Criteria:

• Absolute neutrophil count less than 500 cells/μL
• Pregnancy
• End-stage heart failure (NYHA stage IV)
• Pulmonary embolism with obstructive shock
• Ongoing bleeding
• Atonic coma
• More than 30 points on the MELD scale, class C on the Child-Pugh scale
• HIV infection
• Burns over 10% of the body surface area
• Patients with oncohematological diseases
• Patients with a recognized palliative status or the definition of "metastatic cancer"
• RRT using membranes with a high cutoff point and increased adsorption capacity within 72 hours from the initiation of the first hemoadsorption procedure
• Use of plasma exchange within 72 hours from the initiation of the first hemoadsorption procedure

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

Moscow Multidisciplinary Clinical Center "Kommunarka"OTHER_GOV

Collaborators

Petrovsky National Research Centre of SurgeryOTHER

Bakulev Scientific Center of Cardiovascular SurgeryOTHER_GOV

City clinical hospital named after S. S. Yudin, Moscow City HealthOTHER

Sklifosovsky Institute of Emergency CareOTHER_GOV

City Clinical Hospital No 52, Moscow, RussiaUNKNOWN

Rostov Regional Clinical HospitalOTHER_GOV

stamius@yandex.ru+79265317813

maxbabaev@mail.ru+79160269066

reysi@sklif.mos.ru+79166001362